SubHero Banner
Text

Nucynta® (tapentadol) – Expanded indication

July 3, 2023 - The FDA approved Collegium Pharmaceutical’s Nucynta (tapentadol), for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults and pediatric patients aged 6 years and older with a body weight of at least 40 kg.

Download PDF